DCM
CTMX icon

Delpha Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Delpha Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,106
Closed -$44K – 375
2017
Q4 		$44K Buy
+2,106
New +$43.7K 0.05% 363

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Delpha Capital Management's CTMX Position: Q1 2018 in Review

Delpha Capital Management sold out of CytomX Therapeutics (CTMX) in Q1 2018, closing a stake of 2,106 shares — an estimated $44K sold.

Delpha Capital Management first reported a position in CTMX in Q4 2017 and held it in 1 quarter. The position peaked at $44K in Q4 2017. 141 funds tracked by Wall St. Rank hold CTMX as of Q1 2018.

  • Delpha Capital Management reported no remaining CytomX Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 2,106 CytomX Therapeutics shares in Q1 2018, an estimated $44K.
  • Delpha Capital Management first reported a position in CytomX Therapeutics in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's CytomX Therapeutics position peaked at $44K in Q4 2017.
  • 141 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.